Casper De Clercq

A twenty-year veteran of the medical and life sciences industry, Casper de Clercq observes that innovation in the biotech sector runs in cycles. In the past five years, for instance, there has been extensive adoption of high throughput cell screening assays in the industry. Having joined USVP in 2004, Casper has extensive experience with device innovations in the cardiovascular arena, drug delivery and diagnostics. Given changing conditions in the drug development area, oncology and other therapeutics with an abbreviated regulatory path are of particular interest to Casper. Prior to 2004, Casper was heavily involved in several rounds of financing and the IPO process at Aerogen (AEGN), a specialty pharmaceutical company, where he served as Vice President of Business Development, Sales and Marketing. In 1999 he co-founded Epicor, which was acquired in 2004 by St. Jude Medical at a valuation of more than $200 million. Casper also held senior sales and marketing positions with Heartport (minimally invasive heart surgery) and Diagnostic Products Corporation (immunodiagnostics). At these companies, Casper worked closely with the scientific and engineering teams to define customer requirements and lead product commercialization. Early in his career Casper worked as a strategy consultant for Bain Company, working in Boston, Johannesburg and London. Casper holds a B.A. in Biochemistry from Dartmouth and an M.B.A. and M.A. in Biology/Immunology from Stanford University.